Allergy Therapeutics says US preparations are underway which include two pivotal trials - Manuel Llobert, CEO, Allergy Therapeutics 00:00:00
Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman discuss the interim results for the six months ended 31 December 2021.